What my survival shows, and underscores, is that GBM4 does not have a monolithic outcome, and that full chemo / radio isn't always needed either.
So it stands to reason, that through the use of very careful patient selection, you can slant a trial outcome.
I remain of the firm belief that the trial data presented to the Regulator, was part of a comprehensive fraud attempt to the tune of £2-300M against the NHS and the British Taxpayer.
It is the above reason alone that NWBO's application got seized on by multiple Investigative Agencies .
Market Data 
Markets 
AI
